Gene Therapy Platform

About Seragon Biosciences

Seragon Biosciences is a private, pre-revenue biotech firm leveraging advanced AI and gene therapy platforms to target aging, metabolic disorders, and immunology. The company's core technologies include the GenomeScore™ AI platform for measuring aging and a hybrid gene therapy platform for efficient gene delivery. Operating in the high-growth longevity and gene therapy sectors, Seragon appears to be in a pre-clinical or discovery-stage, building its scientific foundation and seeking partnerships to advance its research programs.

About Polaryx Therapeutics

Polaryx Therapeutics is a clinical-stage biotech company focused on developing disease-modifying treatments for rare pediatric lysosomal storage disorders (LSDs). Its core achievement is advancing PLX-200, an autophagy-inducing small molecule, into a Phase 2 basket trial (SOTERIA) for multiple LSDs, supported by multiple FDA designations including Orphan Drug, Fast Track, and Rare Pediatric Disease. The company's strategy is to build a diversified, multi-modal pipeline—encompassing small molecules and gene therapy—to target both the genetic and downstream pathological features of these diseases, aiming to establish a new standard of care.

Therapeutic Areas

Other Genetic Disorders Drugs